TARS Tarsus Pharmaceuticals, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1819790 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY86.3%
TTM net income YoY-765.3%
TTM EPS YoY-697.0%
Revenue 3-yr CAGR262.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-102.0%
Net margin-102.9%
FCF margin4.8%
EBITDA margin-101.7%
Returns
ROE-319.8%
ROA-135.0%
ROIC (approx.)-330.8%
Asset turnover1.31x
Leverage & solvency
Liabilities / assets79.4%
Debt / equity0.70x
Current ratio1.96x
Interest coverage-80.17x
Cash quality & payout
Operating cash flow / net income-0.07x
Accruals ratio-144.6%
Payout ratio—
Capex / revenue2.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $451.36M | $182.95M | $17.45M | $25.82M | $57.03M |
| R&D expense | $64.32M | $53.39M | $50.31M | $42.62M | $41.71M |
| SG&A expense | $427.32M | $237.31M | $108.70M | $44.95M | $25.40M |
| Operating income | -$70.97M | -$120.57M | -$143.16M | -$62.71M | -$12.16M |
| Interest expense | $8.94M | $7.85M | $3.35M | $2.20M | $0 |
| Pretax income | -$64.36M | -$115.55M | -$135.89M | -$62.09M | -$13.77M |
| Income tax | $2.06M | $0 | $0 | -$4,000 | $55,000 |
| Net income | -$66.42M | -$115.55M | -$135.89M | -$62.09M | -$13.83M |
| EBITDA | -$70.11M | -$119.88M | -$142.41M | -$62.39M | -$11.86M |
| EPS (basic) | -1.59 | -3.07 | -4.62 | -2.52 | -0.67 |
| EPS (diluted) | -1.59 | -3.07 | -4.62 | -2.52 | -0.67 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 41.78M | 37.60M | 29.38M | 24.62M | 20.55M |
| Balance sheet | |||||
| Cash & equivalents | $183.64M | $97.38M | $224.95M | $71.66M | $171.33M |
| Short-term investments | $233.63M | $196.56M | $2.50M | $145.37M | $483,000 |
| Receivables | $85.06M | $46.76M | $16.62M | $0 | $0 |
| Inventory | $4.37M | $2.62M | $3.11M | $0 | — |
| Current assets | $522.78M | $356.70M | $256.13M | $225.38M | $175.95M |
| PP&E, net | $11.66M | $2.31M | $1.47M | $957,000 | $755,000 |
| Intangibles | $7.37M | $8.33M | $3.87M | $0 | — |
| Total assets | $562.16M | $376.99M | $265.49M | $227.86M | $178.91M |
| Current liabilities | $135.69M | $80.61M | $36.94M | $15.43M | $11.48M |
| Long-term debt | $72.44M | $71.84M | $29.82M | $19.43M | $0 |
| Total debt | $72.44M | $71.84M | $29.82M | $19.43M | $0 |
| Total liabilities | $218.73M | $152.46M | $68.50M | $34.96M | $12.18M |
| Shareholders' equity | $343.43M | $224.53M | $196.99M | $192.90M | $166.73M |
| Net debt | -$111.20M | -$25.54M | -$195.13M | -$52.23M | -$171.33M |
| Shares outstanding | 42.55M | 38.35M | 34.21M | 26.70M | 20.70M |
| Cash flow statement | |||||
| Operating cash flow | -$12.45M | -$83.03M | -$117.49M | -$49.03M | $3.75M |
| Capital expenditure | $9.86M | $1.57M | $1.50M | $506,000 | $586,000 |
| Free cash flow | -$22.31M | -$84.59M | -$119.00M | -$49.54M | $3.16M |
| Investing cash flow | -$42.12M | -$199.19M | $140.60M | -$144.63M | -$586,000 |
| Financing cash flow | $143.39M | $154.66M | $130.18M | $93.99M | $21,000 |
| Depreciation & amortization | $855,000 | $685,000 | $744,000 | $326,000 | $300,000 |
| Stock-based compensation | $41.72M | $27.82M | $19.83M | $13.46M | $8.46M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.